A technology developed in Irving J. Bigio’s lab at Boston University and licensed to a company called DermaSensor, received FDA approval in January 2025. This low-cost handheld device, intended for the primary care practitioner, uses light to noninvasively detect skin cancer. Already deployed in hundreds of primary care offices, the DermaSensor device has detected dozens of skin cancers that would have otherwise gone undetected. Bigio is a professor at Boston University, with appointments in the Departments of Biomedical Engineering, Electrical & Computer Engineering, Physics, and Medicine. He leads a research program in biomedical optics, focusing on the development of diagnostic optical spectroscopy for clinical applications, on optical monitoring of cellular dynamics, and on the imaging/sensing of neurological structures and dynamics. He is a fellow of SPIE, Optica, and the American Institute of Medical and Biological Engineering.